Trump administration considering pilot program to cover weight loss drugs under Medicare, Medicaid

Posted on
image

The Trump administration is currently considering implementing a five-year pilot program that would provide coverage for weight-loss drugs under Medicare and Medicaid, according to the Washington Post.

The report is based on documents from the Centers for Medicare and Medicaid Services that describe the proposal. 

The drugs under consideration for coverage include Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro, the documents showed. 

Related News

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.